- Home
- ARVN vs REPL Comparison
ARVN vs REPL Comparison
Compare ARVN & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ARVN | REPL |
|---|---|---|
| Founded | 2015 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 781.0M | 781.3M |
| IPO Year | 2018 | 2018 |
Fundamental Metrics
Financial Performance| Metric | ARVN | REPL |
|---|---|---|
| Price | $13.48 | $7.75 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 23 | 9 |
| Target Price | ★ $18.14 | $11.13 |
| AVG Volume (30 Days) | 753.9K | ★ 1.4M |
| Earning Date | 02-11-2026 | 02-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $312,300,000.00 | N/A |
| Revenue This Year | $10.55 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 93.86 | N/A |
| 52 Week Low | $5.90 | $2.68 |
| 52 Week High | $20.38 | $14.80 |
Technical Indicators
Market Signals| Indicator | ARVN | REPL |
|---|---|---|
| Relative Strength Index (RSI) | 57.38 | 44.44 |
| Support Level | $12.88 | $6.78 |
| Resistance Level | $14.14 | $7.48 |
| Average True Range (ATR) | 0.70 | 0.42 |
| MACD | 0.02 | 0.04 |
| Stochastic Oscillator | 67.89 | 57.89 |
Price Performance
Historical ComparisonAbout ARVN Arvinas Inc.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.
About REPL Replimune Group Inc.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.